Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia

ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties

Guo‐Li Xiong, Jiacai Yi, Li Fu et al. · Nucleic Acids Research · 2021 · 2.7K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

Angela Nebbioso, Nicole Clarke, Emilie Voltz et al. · Nature Medicine · 2004 · 620 citations

Medicine, Oncology, Pharmacology +13

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Vittoria Zoppi, Scott J. Hughes, Chiara Maniaci et al. · Journal of Medicinal Chemistry · 2018 · 333 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +14

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers

Eric J. Duncavage, Molly C. Schroeder, Michele O’Laughlin et al. · New England Journal of Medicine · 2021 · 298 citations · Full text

Life Sciences, Genetics, Oncology +17

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands

David Remillard, Dennis L. Buckley, Joshiawa Paulk et al. · Angewandte Chemie International Edition · 2017 · 292 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +14